{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:37Z","timestamp":1792596817146,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bioorg.2022.106273","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T09:03:46Z","timestamp":1668416626000},"page":"106273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition"],"prefix":"10.1016","volume":"131","author":[{"given":"Peter A.","family":"Halim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souty M.Z.","family":"Sharkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen B.","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.106273_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113489","article-title":"Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells","volume":"221","author":"\u0130bi\u015f","year":"2021","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.bioorg.2022.106273_b0010","doi-asserted-by":"crossref","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(2022) 209-249. https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.bioorg.2022.106273_b0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell."},{"key":"10.1016\/j.bioorg.2022.106273_b0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1387-2656(06)12006-2","article-title":"Inhibitors of signal transduction protein kinases as targets for cancer therapy","volume":"12","author":"Mikalsen","year":"2006","journal-title":"Biotechnology Ann. Rev."},{"key":"10.1016\/j.bioorg.2022.106273_b0025","first-page":"1","article-title":"Anticancer Effects of Chemotherapy and Nature Products","volume":"2","author":"Rana","year":"2017","journal-title":"J. Med. Discov."},{"key":"10.1016\/j.bioorg.2022.106273_b0030","doi-asserted-by":"crossref","first-page":"1900177","DOI":"10.1002\/adtp.201900177","article-title":"Enhanced Cancer Therapy by Combining Radiation and Chemical Effects Mediated by Nanocarriers","volume":"3","author":"Denkova","year":"2020","journal-title":"Adv. Therap."},{"key":"10.1016\/j.bioorg.2022.106273_b0035","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of Multidrug Resistance in Cancer Chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2022.106273_b0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: Back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2022.106273_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","article-title":"Anti-inflammatory agents for cancer therapy","volume":"1","author":"Rayburn","year":"2009","journal-title":"Mol. Cell Pharm."},{"key":"10.1016\/j.bioorg.2022.106273_b0050","doi-asserted-by":"crossref","unstructured":"B. F. Zamarron, W. Chen, Dual roles of immune cells and their factors in cancer development and progression, Int. J. Bio. Sci., 7, (2011) 651\u2013658. https:\/\/www.ijbs.com\/v07p0651.htm.","DOI":"10.7150\/ijbs.7.651"},{"key":"10.1016\/j.bioorg.2022.106273_b0055","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3390\/ijms21072605","article-title":"Anti-Inflammatory Drugs as Anticancer Agents","volume":"21","author":"Zappavigna","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2022.106273_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr1648","article-title":"Oestrogen receptor negative breast cancers exhibit high cytokine content","volume":"9","author":"Chavey","year":"2007","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2022.106273_b0065","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gut.2008.175406","article-title":"Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention","volume":"59","author":"Benamouzig","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2022.106273_b0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejca.2006.01.013","article-title":"Therapeutic potential of cytokine and chemokine antagonists in cancer therapy","volume":"42","author":"Yan","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2022.106273_b0075","doi-asserted-by":"crossref","first-page":"104308","DOI":"10.1016\/j.bioorg.2020.104308","article-title":"Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE2, TNF-\u03b1, IL-6 and histopathological study","volume":"104","author":"Labib","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103029","article-title":"Design, synthesis of celecoxib-tolmetin drug hybrids as selective and potent COX-2 inhibitors","volume":"90","author":"Abdellatif","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bioorg.2018.05.018","article-title":"Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors : Anti-inflammatory, analgesic activities and docking study","volume":"80","author":"Labib","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bioorg.2018.03.011","article-title":"Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2 \/ 5-LOX enzymes: Histopathological and docking studies","volume":"78","author":"Abdelgawad","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.prostaglandins.2011.08.004","article-title":"Regulation of inflammation in cancer by eicosanoids","volume":"96","author":"Greene","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bioorg.2022.106273_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103007","article-title":"Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008\u20132019)","volume":"89","author":"Sharma","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1475-2867-12-53","article-title":"Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo","volume":"12","author":"Dai","year":"2012","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2022.106273_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-27-66","article-title":"Antitumor enhancement of celecoxib, a selective cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing cyclooxygenase-2","volume":"27","author":"Park","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2022.106273_b0115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/auto.6.2.11124","article-title":"Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells","volume":"6","author":"Huang","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.bioorg.2022.106273_b0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.arcmed.2005.11.014","article-title":"Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines","volume":"37","author":"Vital-Reyes","year":"2006","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.bioorg.2022.106273_b0125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450119666180803121737","article-title":"Celecoxib in cancer therapy and prevention\u2013review","volume":"20","author":"To\u0142oczko-Iwaniuk","year":"2019","journal-title":"Curr. drug targets"},{"key":"10.1016\/j.bioorg.2022.106273_b0130","doi-asserted-by":"crossref","first-page":"21268","DOI":"10.18632\/aging.203443","article-title":"Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism","volume":"13","author":"Yin","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bioorg.2022.106273_b0135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bmcl.2015.11.040","article-title":"Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR\/HER-2 kinase inhibitors","volume":"26","author":"Tao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106273_b0140","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bmcl.2007.12.035","article-title":"Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors","volume":"18","author":"Ducray","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106273_b0145","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bmc.2013.01.074","article-title":"Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor","volume":"21","author":"Miyamoto","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0150","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejmech.2013.10.077","article-title":"Design and synthesis of pyrazole-oxindole conjugates targeting tubulin polymerization as new anticancer agents","volume":"92","author":"Kamal","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0160","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.bmc.2019.01.011","article-title":"Synthesis and biological evaluation of pyrazole linked benzothiazole-\u03b2-naphthol derivatives as topoisomerase I inhibitors with DNA binding ability","volume":"27","author":"Nagaraju","year":"2019","journal-title":"Bioorg Med Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0165","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.arabjc.2015.12.006","article-title":"Ultrasound-assisted synthesis and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors","volume":"12","author":"Nitulescu","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0170","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1016\/j.bmc.2015.07.010","article-title":"Synthesis and apoptotic activity of new pyrazole derivatives in cancer cell lines","volume":"23","author":"Nitulescu","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0175","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/14656566.2012.688029","article-title":"Crizotinib in the treatment of non-small-cell lung cancer","volume":"13","author":"Forde","year":"2012","journal-title":"Expert opin. pharmacother."},{"key":"10.1016\/j.bioorg.2022.106273_b0180","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.2147\/OTT.S165511","article-title":"Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date","volume":"11","author":"Akamine","year":"2018","journal-title":"OncoTargets ther"},{"key":"10.1016\/j.bioorg.2022.106273_b0185","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/molecules25061364","article-title":"Natural and biomimetic antitumor pyrazoles, A perspective","volume":"25","author":"Santos","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2022.106273_b0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/ajhp\/zxz329","article-title":"Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer","volume":"77","author":"Roubal","year":"2020","journal-title":"Am, J, Health Syst, Pharm."},{"key":"10.1016\/j.bioorg.2022.106273_b0195","first-page":"149","article-title":"Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma Bioorg","volume":"78","author":"Harras","year":"2018","journal-title":"Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2022.106273_b0200","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2022.106273_b0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ejmech.2018.02.033","article-title":"Potent hydrazone derivatives targeting esophageal cancer cells","volume":"148","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130722","article-title":"Synthesis and cytotoxicity screening of some synthesized hybrid nitrogen molecules as anticancer agents","volume":"1242","author":"Mourad","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2022.106273_b0215","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/tx900111y","article-title":"Miao Novel complex of copper and a salicylaldehyde pyrazole hydrazone derivative induces apoptosis through up-regulating Integrin \u03b24 in vascular endothelial cells","volume":"22","author":"Fan","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2022.106273_b0220","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/14756366.2018.1504041","article-title":"Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents","volume":"33","author":"\u00c7al\u0131\u015fkan","year":"2018","journal-title":"J. Enz. Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejmech.2019.05.071","article-title":"Tetrazole hybrids with potential anticancer activity","volume":"178","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0230","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/14756366.2018.1503654","article-title":"Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinoma as VEGFR-2 Inhibitors","volume":"33","author":"AbdElhameid","year":"2018","journal-title":"J. Enz. Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0235","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/jhet.2707","article-title":"derivational, structural, and biological studies of some new pyrazolyl, isoxazolyl, pyrimidinyl, pyridazinyl, and pyridopyridazinyl from 4-substituted antipyrine","volume":"54","author":"Fadda","year":"2017","journal-title":"J. Het. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0240","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bioorg.2018.03.030","article-title":"Design, synthesis and evaluation of some pyrazolo [3, 4-d] pyrimidines as anti-inflammatory agents","volume":"78","author":"Tageldin","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0245","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/jhet.3522","article-title":"Synthesis and pharmacological investigations of novel pyrazolyl and hydrazonoyl cyanide benzimidazole entities","volume":"56","author":"Khalifa","year":"2019","journal-title":"J. Het. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0250","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1002\/jhet.4076","article-title":"Design, synthesis, and in vitro anticancer screening of novel pyrazolinyl-pyrazole\/1, 2, 3-triazole hybrids","volume":"57","author":"Ismail","year":"2020","journal-title":"J. Het. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0255","first-page":"258","article-title":"Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy","volume":"5","author":"Zargar","year":"2019","journal-title":"Chronic Dis. Transl. Med"},{"key":"10.1016\/j.bioorg.2022.106273_b0260","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmech.2018.04.014","article-title":"Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies","volume":"151","author":"Nasr","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0265","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2022.106273_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2121-14-32","article-title":"Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis","volume":"14","author":"Brentnall","year":"2013","journal-title":"BMC cell biology"},{"key":"10.1016\/j.bioorg.2022.106273_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104960","article-title":"Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity","volume":"112","author":"Mohamed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.bioorg.2022.106273_b0285","doi-asserted-by":"crossref","unstructured":"Z. Xiao, C. Chu, L. Zhou, Z. Zhou, Q. Zhang, F. Yang, Z. Yang, P. Zheng, S. Xu, W. Zhu, Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors, Bioorg. Med. Chem. 28 (2020) 115669. https:\/\/doi.org\/10.1016\/j.bmc.2020.115669.","DOI":"10.1016\/j.bmc.2020.115669"},{"key":"10.1016\/j.bioorg.2022.106273_b0290","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-09-3528","article-title":"Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron","volume":"70","author":"Reinhold","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2022.106273_b0295","first-page":"c18","article-title":"Synthesis of novel pyrazole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I\/II activities","author":"Feng","year":"2018","journal-title":"Chem. Pharm. Bul."},{"key":"10.1016\/j.bioorg.2022.106273_b0300","unstructured":"http:\/\/swissadme.ch."},{"key":"10.1016\/j.bioorg.2022.106273_b0305","unstructured":"http:\/\/molsoft.com\/mprop\/."},{"key":"10.1016\/j.bioorg.2022.106273_b0310","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejmech.2017.12.065","article-title":"Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study","volume":"144","author":"Moussa","year":"2018","journal-title":"Eur. J. med. chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0315","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1021\/jm0302391","article-title":"Design, Synthesis, and Biological Evaluation of 6-Substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: A Novel Class of Diarylheterocyclic Selective Cyclooxygenase-2 Inhibitors","volume":"46","author":"Rao","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0320","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2174\/1573406417666210809162636","article-title":"Design and Synthesis of Novel Ibuprofen Derivatives as Selective COX-2 Inhibitors and Potential Anti-Inflammatory Agents: Evaluation of PGE2, TNF-\u03b1, IL-6 and Histopathological Study","volume":"18","author":"Halim","year":"2022","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01404408","article-title":"A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures","volume":"11","author":"Edmondson","year":"1988","journal-title":"Tiss. Cult. Meth."},{"key":"10.1016\/j.bioorg.2022.106273_b0330","article-title":"Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors","volume":"97","author":"Abdoa","year":"2020","journal-title":"Bioorg. Chem"},{"key":"10.1016\/j.bioorg.2022.106273_b0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14756366.2021.1998023","article-title":"Synthesis and biological evaluation of halogenatedphenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer","volume":"37","author":"Halim","year":"2022","journal-title":"J. Enz. Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0340","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/ic701735q","article-title":"Luminescent Biological Probes Derived from Ruthenium(II) Estradiol Polypyridine Complexes","volume":"47","author":"Lo","year":"2008","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2022.106273_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105591","volume":"120","author":"Abdelall","year":"2022","journal-title":"Bioorg. Chem"},{"key":"10.1016\/j.bioorg.2022.106273_b0350","first-page":"509","article-title":"Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of in-silico and in-vitro cytotoxicity methods, Res","volume":"13","author":"Nasab","year":"2018","journal-title":"Pharm. Sci."},{"key":"10.1016\/j.bioorg.2022.106273_b0355","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ejmech.2015.08.032","article-title":"Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity","volume":"102","author":"Majumdar","year":"2015","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822006794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822006794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:36:17Z","timestamp":1758616577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822006794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":71,"alternative-id":["S0045206822006794"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106273","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106273"}}